chufangao/CTO huggingface dataset:
Clinical trial NCT04965272: A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Official title: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose, Phase 2 Study Evaluating the Safety and Efficacy of Cariprazine as an Adjunctive Therapy to Antidepressant Therapies (ADTs), in the Treatment of Subjects With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADT Alone
Acronym: CAR aGAD Ph 2
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Strategic Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-08-18
Primary completion date: 2021-08-24
Completion date: 2021-08-24
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT03473977: Benralizumab for Eosinophilic Gastritis (BEGS)
Official title: A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis
Acronym: BEGS
Sponsor: Children's Hospital Medical Center, Cincinnati (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-23
Primary completion date: 2020-06-22
Completion date: 2022-01-12
Plan to share individual participant data: NO
Clinical trial NCT04103814: Effect of Topical CBD Cream for Degenerative Hallux Disorders
Official title: Effect of Topical CBD Oil on Pain Scores for Hallux Disorders: A Randomized Controlled Trial
Sponsor: Rush University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Lack of resources to continue enrollment
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-20
Primary completion date: 2023-05-15
Completion date: 2023-05-15
Baseline population: study terminated as it was too resource intensive to obtain pain scores from patients
Plan to share individual participant data: NO
Clinical trial NCT03978520: A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
Official title: A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Acronym: SLEek
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 341.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-07-25
Primary completion date: 2022-01-19
Completion date: 2022-07-14
Baseline population: Full Analysis Set: all randomized participants who received at least 1 dose of study drug
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03545165: 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Official title: Phase I/II Dose-Escalation Trial of Combination Fractionated-dose 177Lu-J591 and 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor withdrawal
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-18
Primary completion date: 2020-07-15
Completion date: 2020-07-15
Limitations and caveats: The study was terminated early due to sponsor withdrawal (PSMA-617 no longer available for purchase).
Clinical trial NCT02622321: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
Official title: A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors
Acronym: HAVEN 1
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 113.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-11-18
Primary completion date: 2016-10-25
Completion date: 2020-12-01
Baseline population: All enrolled participants
Clinical trial NCT05592223: Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
Official title: A Phase I Single Site Open Label Clinical Trial for the Development of a Human BCG Challenge Model to Assess TB Drugs and Vaccines.
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-12-06
Primary completion date: 2023-08-23
Completion date: 2023-12-01
Plan to share individual participant data: YES
IPD sharing description: Sharing de-identified AE's/SAE's from all individual participants with Merck \& Co during the trial.
IPD time frame: During the participants active study period.
Clinical trial NCT03596125: Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP)
Official title: Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth
Sponsor: Nantes University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: difficulty of recruitment
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-05
Primary completion date: 2021-11-11
Completion date: 2021-11-11
Clinical trial NCT04502706: Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
Official title: A Phase 1 Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision to discontinue development of this molecule
Enrollment: 9.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-11-17
Primary completion date: 2022-03-31
Completion date: 2022-03-31
Plan to share individual participant data: NO
Clinical trial NCT04702789: Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Official title: Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination to the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination, in Primary Open Angle Glaucoma or Ocular Hypertension Patients.
Acronym: PRO-122
Sponsor: Laboratorios Sophia S.A de C.V. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: For interests of sponsor.
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-19
Primary completion date: 2023-11-23
Completion date: 2023-11-23
Plan to share individual participant data: NO
Clinical trial NCT01345539: Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation
Official title: Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Participant enrollment was negatively impacted by medical oncology treatment with systemic therapy alone and accrual to other clinical trials.
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-06-07
Primary completion date: 2022-05-03
Completion date: 2022-10-20
Baseline population: All patients enrolled in the study.
Plan to share individual participant data: NO
Clinical trial NCT03964415: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
Acronym: MOSAICO
Sponsor: Janssen Vaccines & Prevention B.V. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 3900.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-31
Primary completion date: 2023-08-10
Completion date: 2023-08-10
Baseline population: The full analysis set (FAS) set included all randomized participants who received at least one vaccine administration.
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04770155: Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1
Official title: Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1
Acronym: UMMC_Pilot
Sponsor: University of Mississippi Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Despite significant effort, we were unable to obtain the supply of drugs and supplements needed for the various arms of this Clinical Trial.
Enrollment: 8.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-05-27
Primary completion date: 2021-09-20
Completion date: 2021-09-20
Baseline population: The only data collected were baseline measurements and no participants were ever given either intervention; the investigator was never able to obtain the treatments to use for the planned intervention arm of the study, resulting in its termination. Upon resigning of his Instructor position at UMMC, the investigator backed up the baseline data files on an external hard drive. Unfortunately, some issue with the external hard drive corrupted the files, making them no longer accessible.
Limitations and caveats: The only data collected were baseline measurements and no participants were ever given either intervention; the investigator was never able to obtain the treatments to use for the planned intervention arm of the study, resulting in its termination.
Plan to share individual participant data: YES
IPD sharing description: Doppler ultrasound videos, analog-digital recordings, participants' characteristics, and randomization codes will be available in an unidentified format.
IPD time frame: On Jan 1st, 2025 for one year.
IPD access criteria: By request.
Clinical trial NCT04655391: Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
Official title: A Pilot/Phase 1b Study of Glasdegib-Based Treatment Combinations in Adult Patients With Relapsed AML Post Allogeneic Hematopoietic Cell Transplantation
Sponsor: City of Hope Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Drug availability
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-06-25
Primary completion date: 2023-12-15
Completion date: 2023-12-15
Clinical trial NCT00230607: Study of the Effects of Fabrazyme Treatment on Lactation and Infants
Official title: A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Per FDA decision, the 2003 Post Marketing commitment has been fulfilled.
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2006-05-28
Primary completion date: 2024-02-09
Completion date: 2024-02-09
Baseline population: Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.
Limitations and caveats: This is a rare disease study, with very few participants enrolled. The study was terminated by the Sponsor. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04117880: A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia
Official title: Nonsense Mutation Aniridia: An Ataluren (PTC124) Phase 2 Extension Study
Sponsor: PTC Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study cancelled before protocol was implemented.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-31
Primary completion date: 2021-01-31
Completion date: 2021-01-31
Clinical trial NCT05443464: Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)
Official title: A Phase I Safety Study of Single Dose Allogeneic Bone Marrow Derived MSCs for Steroid Refractory Acute Graft vs. Host Disease
Sponsor: Ossium Health, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: OSSM-001 will not be used in this program moving forward.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-06-05
Primary completion date: 2024-06-10
Completion date: 2024-10-14
Plan to share individual participant data: NO
Clinical trial NCT06484881: Clinical Study of Probiotic Treatment for Androgenetic Alopecia
Official title: Clinical Study of Probiotic Treatment for Androgenetic Alopecia
Sponsor: Applied Biology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Concern about formulation patent
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-09-15
Primary completion date: 2024-10-10
Completion date: 2024-10-10
Plan to share individual participant data: NO
Clinical trial NCT03133897: Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study
Official title: Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study
Sponsor: Children's Hospital of Eastern Ontario (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: it was felt by the sponsoring institution that the current standard of oversight expected by the Health Canada regulations, would not be possible to achieve
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-05
Primary completion date: 2019-08-02
Completion date: 2020-03-11
Plan to share individual participant data: NO
Clinical trial NCT04918771: Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old
Official title: Multicenter Double Blind Placebo-controlled Parallel-group Randomized Clinical Study of Efficacy and Safety of Raphamin in the Treatment of Acute Respiratory Viral Infection in Children Aged 12-18 Years Old
Sponsor: Materia Medica Holding (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 435.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-29
Primary completion date: 2023-07-21
Completion date: 2023-07-21
Clinical trial NCT04084665: Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
Official title: A Pilot Study to Examine Safety, Activity and Biomarkers in Participants With Hidradenitis Suppurativa Receiving a Previously Tested Subcutaneous Dose of Anti-IL-23 Monoclonal Antibody Guselkumab.
Sponsor: Rockefeller University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: COVID-19 Pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-01
Primary completion date: 2020-07-30
Completion date: 2020-07-30
Plan to share individual participant data: NO
Clinical trial NCT02181413: A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Official title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 656.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-01
Primary completion date: 2018-04-16
Completion date: 2023-09-08
Baseline population: Intent-to-Treat (ITT) population was defined as all participants who were randomized and had post randomization data.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04277936: Pharmacologic Modulation of Hippocampal Activity in Psychosis
Official title: Pharmacologic Modulation of Hippocampal Activity in Psychosis
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was redesigned and submitted as a new protocol (NCT04559529).
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-11
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Baseline population: Data were collected for a single subject, but study design was changed and study was discontinued. No data were analyzed.
Plan to share individual participant data: NO
Clinical trial NCT04014712: O2 Transport and Utilization in Health and Lung Disease
Official title: Role of Nitric Oxide Coupling in Muscle Dysfunction With COPD
Sponsor: University of Massachusetts, Amherst (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Unable to recruit due to COVID-19 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Plan to share individual participant data: YES
IPD time frame: 6 months post-publication
IPD access criteria: Within 6 months after the data have been published, and upon written request, a limited, de-identified, anonymized dataset will be created pursuant to the Data use Agreement.
Clinical trial NCT04379518: Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Official title: Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19
Sponsor: Roswell Park Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: working on revision to protocol
Enrollment: 64.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2020-11-17
Primary completion date: 2023-11-17
Completion date: 2023-11-17
Clinical trial NCT05392751: Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Official title: Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Sponsor: Endogena Therapeutics, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study terminated by the Sponsor. All study participants completed at least 12 months of safety follow-up instead of 24 mo. The reason for earlier termination was due to a corporate decision; not any safety concerns of EA-2353.
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-02
Primary completion date: 2024-04-24
Completion date: 2024-04-24
Plan to share individual participant data: NO
Clinical trial NCT04372641: Testing the Safety of CB-5339 in Patients With Cancer
Official title: A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Other - Clinical development of the agent has been discontinued
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-18
Primary completion date: 2021-07-12
Completion date: 2021-07-12
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.